^
Association details:
| Biomarker: | BCR-ABL1 T315I |
|---|---|
| Cancer: | Leukemia |
| Drug: | mirdametinib (PD-0325901) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia
Published date:
06/29/2023
Excerpt:
Additionally, the allosteric activation of nuclear ABL1 was consistently found to enhance the anti-leukemic effects of the MEK1/2 inhibitor Mirdametinib, which when combined with ATO, significantly prolonged the survival of mice bearing BCR::ABL1-T315I-induced leukemia.
DOI:
10.1038/s41375-023-01940-x
